胰升血糖素样肽1受体激动剂心血管获益的研究进展

Recent advances in the cardiovascular benefits of GLP-1 receptor agonists

糖尿病是心血管疾病(CVD)的主要危险因素,心血管并发症是T2DM患者死亡的首要原因,近年来新型抗糖尿病药物的心血管安全性及获益受到更多关注。胰升血糖素样肽1受体激动剂(GLP⁃1RA)作为治疗糖尿病的新型药物,除提高肠促胰素活性降糖以保护心肌作用外,还通过其他机制发挥心血管系统保护作用。GLP⁃1RA对缺血性心脏病患者的心功能及不同心肌损伤的动物模型均起到一定的保护效应,具体机制有待进一步研究。本文对近年来GLP⁃1RA对心血管系统的影响进行综述,为临床防治CVD提供理论依据。

Diabetes is a major risk factor for cardiovascular disease(CVD),and its related cardio⁃vascular complications are the leading cause of death in type 2 diabetes(T2DM)patients.In recent years,more and more attention has been paid to the cardiovascular safety and benefits of new antihyperglycemic drugs.As a new class of diabetes drug,glucagon⁃like peptide⁃1 receptor agonist(GLP⁃1RA)not only has the myocardial protective effect by improving the activity of glucagon⁃like peptide through glucose reduction,but also plays a protective role in the cardiovascular system by other mechanisms.Clinical studies in human beings and basic experiments have found that GLP⁃1RA has certain protective effects in the cardiac function in patients with ischemic heart disease and in animal models with different myocardial injuries.However,the specific mechanism of these productive effects remains to be further elucidated.This review will briefly sum⁃marize recent studies of the GLP⁃1RA effects on cardiovascular system,and provide new ideas and theoreti⁃cal basis for clinical prevention and treatment of CVD.